CRISPR/Cas9 gene editing for the creation of an MGAT1 deficient CHO cell line to control HIV-1 vaccine glycosylation
G. Byrne, S. M. O'Rourke, D. L. Alexander, B. Yu, R. Doran, M. Wright, Q. Chen, P. Azadi, P. W. Berman
This paper develops a CRISPR/Cas9-edited CHO cell line deficient in MGAT1 to produce HIV-1 gp120 with early glycosylation intermediates, enhancing binding to glycan-dependent broadly neutralizing antibodies.
bioRxiv · Jul 13, 2018Bioengineering